These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 15199455)

  • 1. Genetic regulation of warfarin metabolism and response.
    Daly AK; Aithal GP
    Semin Vasc Med; 2003 Aug; 3(3):231-8. PubMed ID: 15199455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interindividual variability in sensitivity to warfarin--Nature or nurture?
    Loebstein R; Yonath H; Peleg D; Almog S; Rotenberg M; Lubetsky A; Roitelman J; Harats D; Halkin H; Ezra D
    Clin Pharmacol Ther; 2001 Aug; 70(2):159-64. PubMed ID: 11503010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of oral anticoagulants.
    Daly AK; King BP
    Pharmacogenetics; 2003 May; 13(5):247-52. PubMed ID: 12724615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants.
    Visser LE; van Schaik RH; van Vliet M; Trienekens PH; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
    Clin Pharmacol Ther; 2005 Jun; 77(6):479-85. PubMed ID: 15961979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose.
    Herman D; Locatelli I; Grabnar I; Peternel P; Stegnar M; Mrhar A; Breskvar K; Dolzan V
    Pharmacogenomics J; 2005; 5(3):193-202. PubMed ID: 15824753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystal structure of human cytochrome P450 2C9 with bound warfarin.
    Williams PA; Cosme J; Ward A; Angove HC; Matak Vinković D; Jhoti H
    Nature; 2003 Jul; 424(6947):464-8. PubMed ID: 12861225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9.
    He M; Korzekwa KR; Jones JP; Rettie AE; Trager WF
    Arch Biochem Biophys; 1999 Dec; 372(1):16-28. PubMed ID: 10562412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2C9 polymorphism: prevalence in healthy and warfarin-treated Malay and Chinese in Malaysia.
    Ngow HA; Wan Khairina WM; Teh LK; Lee WL; Harun R; Ismail R; Salleh MZ
    Singapore Med J; 2009 May; 50(5):490-3. PubMed ID: 19495518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of pharmacogenetics in anticoagulation therapy.
    Hill CE; Duncan A
    Clin Lab Med; 2008 Dec; 28(4):513-24. PubMed ID: 19059059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.
    Wadelius M; Sörlin K; Wallerman O; Karlsson J; Yue QY; Magnusson PK; Wadelius C; Melhus H
    Pharmacogenomics J; 2004; 4(1):40-8. PubMed ID: 14676821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Warfarin therapy in a patient homozygous for the CYP2C9 3 allele.
    Ablin J; Cabili S; Lagziel A; Peretz H
    Isr Med Assoc J; 2002 Feb; 4(2):139-41. PubMed ID: 11875991
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements.
    Saraeva RB; Paskaleva ID; Doncheva E; Eap CB; Ganev VS
    J Clin Pharm Ther; 2007 Dec; 32(6):641-9. PubMed ID: 18021343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.
    Schalekamp T; Oosterhof M; van Meegen E; van Der Meer FJ; Conemans J; Hermans M; Meijerman I; de Boer A
    Clin Pharmacol Ther; 2004 Nov; 76(5):409-17. PubMed ID: 15536456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort.
    Moridani M; Fu L; Selby R; Yun F; Sukovic T; Wong B; Cole DE
    Clin Biochem; 2006 Jun; 39(6):606-12. PubMed ID: 16630605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol].
    Márk L; Márki-Zay J; Fodor L; Kondacs A; Paragh G; Katona A
    Orv Hetil; 2005 Apr; 146(16):739-43. PubMed ID: 15889670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.
    García-Martín E; Martínez C; Tabarés B; Frías J; Agúndez JA
    Clin Pharmacol Ther; 2004 Aug; 76(2):119-27. PubMed ID: 15289789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variant CYP2C9 alleles and warfarin concentrations in patients receiving low-dose versus average-dose warfarin therapy.
    Redman AR; Zheng J; Shamsi SA; Huo J; Kelly EJ; Ho RJ; Ritchie DM; Hon YY
    Clin Appl Thromb Hemost; 2008 Jan; 14(1):29-37. PubMed ID: 17895500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytochrome P450 2C9 polymorphism and acenocoumarol therapy.
    Mark L; Marki-Zay J; Fodor L; Hajdara I; Paragh G; Katona A
    Kardiol Pol; 2006 Apr; 64(4):397-402; discussion 403-4. PubMed ID: 16699986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The influence of CYP2C9 genetic polymorphism on the pharmacokinetics and pharmacodynamics of warfarin in patients with constant atrial fibrillation].
    Sychev DA; Mikheeva IuA; Kropacheva ES; Ignat'ev IV; Bulytova IuM; Ramenskaia GV; Dobrovol'skiĭ AB; Panchenko EP; Kukes VG
    Klin Med (Mosk); 2007; 85(1):57-60. PubMed ID: 17419358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytochrome P4502C9 genotype in Southeast Anatolia and possible relation with some serum tumour markers and cytokines.
    Yilmaz N; Erbağci AB; Aynacioğlu AS
    Acta Biochim Pol; 2001; 48(3):775-82. PubMed ID: 11833786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.